BioSpace News Archive

Nordic Nanovector ASA announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Jefferies Virtual London Healthcare Conference, taking place 17-19 November 2020.

Phase 3 studies for diabetic macular edema and retinal vein occlusion enrolling well and on track for topline results also in 2022

Commercialization preparedness activities continuing ahead of December 30 PDUFA date for FUROSCIX® (furosemide injection) for subcutaneous administration

Study of DEXYCU vs. Prednisolone eye drops shows high patient preference for DEXYCU regimen with statistically better inflammation control, pain, visual acuity outcomes in DEXYCU group

Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population with approximately 200 patients enrolled to date

Synthetic Biologics, Inc., a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases in areas of high unmet need, announced it has engaged A.G.P./Alliance Global Partners to assist the Company in exploring and evaluating a range of strategic options.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T® therapies.

Chesapeake Urology, has enrolled their first patient in the VESAIR Clinical Trial.

Accenture (NYSE: ACN) has helped the U.S. subsidiary of Swedish pharmaceutical company Orexo launch its first digital therapeutic, vorvida®, for patients in the United States dealing with problematic alcohol use

Alligator Bioscience (“Alligator”) (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. (“Aptevo”) (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietar